Rallybio Corp CFO Transitions to Part-Time Ahead of Avenzo Merger

What Happened
Rallybio Corporation filed an 8-K on Sept. 9, 2026 disclosing that Jonathan Lieber, the company’s Chief Financial Officer and Principal Financial Officer, will transition to part-time employment effective Sept. 15, 2026 while retaining his CFO/PFO titles, duties and authority. Under an Employment Side Letter dated Sept. 8, 2026, Mr. Lieber’s base salary after the transition will be $420,000 and he will be eligible for company benefits but will not receive an annual bonus for 2026 or any subsequent year during which he remains employed. His employment is set to terminate upon the closing of Rallybio’s pending business combination with Avenzo Therapeutics, Inc. (per the May 31, 2026 merger agreement), unless earlier terminated, and any severance payable will follow his existing employment agreement and amendment previously filed with the SEC. The Employment Side Letter is filed as Exhibit 10.1 to the 8-K.

Key Details

• Transition effective date: September 15, 2026.
• Post-transition base salary: $420,000.
• No annual bonus entitlement for 2026 or later years while employed.
• Employment terminates on closing of pending merger with Avenzo (Agreement dated May 31, 2026); severance governed by existing agreements.

Why It Matters
This filing signals a change in Rallybio’s executive time commitment and compensation structure for its CFO during a period when the company is pursuing a business combination. Investors should note the reduced variable pay (no annual bonus) and that the CFO’s employment is tied to the timing of the Avenzo merger, which could affect leadership continuity and compensation expense around the transaction closing. The details of severance and the side letter are publicly filed for review (Exhibit 10.1).